Tirzepatide is a GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide) dual agonist; its role in the treatment of liver fibrosis besides the resolution of MASH was hinted by a phase 2, dose-finding, multicenter, double-blind, randomized trial by Loomba et al. who documented an improvement of at least one stage of fibrosis in 55% of patients undergoing treatment with 5 mg of tirzepatide, 51% with 10 mg, and with 15 mg of tirzepatide, versus 30% with placebo. Here, GLP1R is linked to Hepatic fibrosis.